Low CD27 expression in plasma cell dyscrasias correlates with high-risk disease: An immunohistochemical analysis

American Journal of Clinical Pathology

Volumn 126, Issue 4, 2006, Pages 545-551

  Morgan, Terry K ^a,c   Zhao, Shuchun ^a   Chang, Karen L ^b   Haddix, Terri L ^a   Domanay, Elisabeth ^a   Cornbleet, P Joanne ^a   Arber, Daniel A ^a   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

CD27; MGUS; Monoclonal gammopathy of undetermined significance; Myeloma; Plasma cell leukemia; Plasmacytoma

Indexed keywords

CD20 ANTIGEN; CD27 ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; COMPLEMENTARY DNA; KI 67 ANTIGEN; PROTEIN P27; SYNDECAN 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW BIOPSY; DISEASE COURSE; DNA MICROARRAY; GENE EXPRESSION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMA CELL DYSCRASIA; PLASMA CELL LEUKEMIA; PLASMACYTOMA; PRIORITY JOURNAL; SURVIVAL;

EID: 33749319345     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/ELGMGX81C2UTP55R     Document Type: Article

References (40)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749-757.
2. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346:564-569.
3. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma: implications for progression to overt multiple myeloma. Hematol Oncol Clin North Am. 1997;11:71-87.
4. Garcia-Sanz R, Orfao A, Gonzalez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood. 1999;93:1032-1037.
5. Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med. 1987;83:1062-1068.
6. Hayman SR, Fonseca R. Plasma cell leukemia. Curr Treat Options Oncol. 2001;2:205-216.
7. Witzig TE, Kimlinger T, Stenson M, et al. Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 1998;31:167-175.
8. Costes V, Magen V, Legouffe E, et al. The Mil5 monoclonal antibody (anti-syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens. Hum Pathol. 1999;30:1405-1411.
9. O'Connell FP, Pinkus JL, Pinkus GS. CD138 (syndecan-1), a plasma cell marker: immunohistochemical profile in hematopoietic and nonhematopoietic neoplasms. Am J Clin Pathol. 2004;121:254-263.
10. Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745-1757.
11. Claudio JO, Masih-Khan E, Tang H, et al. A molecular compendium of genes expressed in multiple myeloma. Blood. 2002;100:2175-2186.
12. Guikema JE, Hovenga S, Vellenga E, et al. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. Br J Haematol. 2003;121:36-43.
13. Bigler RD, Bushkin Y, Chiorazzi N. S152 (CD27): a modulating disulfide-linked T cell activation antigen. J Immunol. 1988;141:21-28.
14. Jung J, Choe J, Li L, et al. Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10. Eur J Immunol. 2000;30:2437-2443.
15. Hintzen RQ, Lens SM, Beckmann MP, et al. Characterization of the human CD27 ligand, a novel member of the TNF gene family. J Immunol. 1994;152:1762-1773.
16. Agematsu K, Nagumo H, Oguchi Y, et al. Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction. Blood. 1998;91:173-180.
17. Raman VS, Akondy RS, Rath S, et al. Ligation of CD27 on B cells in vivo during primary immunization enhances commitment to memory B cell responses. J Immunol. 2003;171:5876-5881.
18. Prasad KV, Ao Z, Yoon Y, et al. CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein. Proc Natl Acad Sci U S A. 1997;94:6346-6351.
19. Katayama Y, Sakai A, Oue N, et al. A possible role for the loss of CD27-CD70 interaction in myelomagenesis. Br J Haematol. 2003;120:223-234.
20. Guikema JE, Vellenga E, Abdulahad WH, et al. CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases. Br J Haematol. 2004;124:299-308.
21. Kremer M, Ott G, Nathrath M, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol. 2005;205:92-101.
22. 1 cyclin-dependent kinases. Genes Dev. 1995;9:1149-1163.
23. Van Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19). Blood. 1990;76:377-382.
24. Martin P, Santon A, Bellas C. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis. Histopathology. 2004;44:375-380.
25. Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients: implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152:1655-1665.
26. Schwartz TH, Rhiew R, Isaacson SR, et al. Association between intracranial plasmacytoma and multiple myeloma: clinicopathological outcome study. Neurosurgery. 2001;49:1039-1044.
27. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
28. Camp RL, Charette LA, Rimm DL. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000;80:1943-1949.
29. Masir N, Jones M, Pozzobon M, et al. Expression pattern of FCRL (FREB, FcRX) in normal and neoplastic human B cells. Br J Haematol. 2004;127:335-343.
30. Chen ZM, Wang HL. Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol. 2004;28:1352-1359.
31. Gutierrez NC, Hernandez JM, Garcia JL, et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia. 2001;15:840-845.
32. Liebisch P, Viardot A, Bassermann N, et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol. 2003;122:193-201.
33. Padanilam BJ, Lewington AJ, Hammerman MR. Expression of CD27 and ischemia/reperfusion-induced expression of its ligand Siva in rat kidneys. Kidney Int. 1998;54:1967-1975.
34. Py B, Slomianny C, Auberger P, et al. Siva-1 and an alternative splice form lacking the death domain, Siva-2, similarly induce apoptosis in T lymphocytes via a caspase-dependent mitochondrial pathway. J Immunol. 2004;172:4008-4017.
35. Akiba H, Nakano H, Nishinaka S, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem. 1998;273:13353-13358.
36. Xu FH, Sharma S, Gardner A, et al. Interleukin-6-induced inhibition of multiple myeloma cell apoptosis: support for the hypothesis that protection is mediated via inhibition of the JNK/SAPK pathway. Blood. 1998;92:241-251.
37. Pene F, Claessens YE, Muller O, et al. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene. 2002;21:6587-6597.
38. Witzig TE, Timm M, Larson D, et al. Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders. Br J Haematol. 1999;104:131-137.
39. Pellat-Deceunynck C, Barille S, Jego G, et al. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma. Leukemia. 1998;12:1977-1982.
40. Perez-Andres M, Almeida J, Martin-Ayuso M, et al. Clonal plasma cells from monoclonal gammopathy of undetermined significance, multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment. Leukemia. 2005;19:449-455.